Aegerion shares do not reflect intrinsic value of its business, says Cowen Cowen noted Aegerion is facing perception difficulties as of late but believes the shares do not fully reflect the intrinsic value of its business. The firm sees a more disciplined approach to communications, and noted the company's presentation of Juxtapid's efficacy as well as the company's view of its opportunity in the pediatric HoFH space.
Aegerion price target lowered to $46 from $66 at Leerink Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.